



Redberry raises one million euros to accelerate the roll-out of its rapid microbiology solutions.

Illkirch, France (October 27th, 2022) - Specializing in rapid microbiology, Redberry announces that it has secured one million euros for refinancing.

Alongside the Redberry founders, new investors also took part in this first round, including SODIV and Business Angels. CIC Est leverages on this fundraising.

This operation aims to accelerate the industrial production and commercial development of Redberry. Already present in the drinking water and pharmaceutical markets, the company based in the East of France currently serves its first customers in Europe and plans to extend its commercial offer to Japan and the United States in 2023.

Unprecedented performances already recognized in the water and pharmaceutical industries

The first solution successfully marketed by Redberry in 2020 allows automated monitoring of the microbial load within ten minutes compared to several days with traditional methods. Already adopted by several leaders in the production of drinking water, it is currently also being validated and deployed in the fields of pharmaceutical products and fast-moving consumer goods.

Redberry announced in July 2022 the first quantitative *E. coli* detection test delivering same-day results for the control of drinking water. In the pharmaceutical industry, current trials with leading global players prepare the validation of a sterility test for vaccines and drugs that would at least halve current release time.

This new funding will support the ramp-up of sales.

Since its creation in 2017, Redberry has carried out its technical and commercial development by financing from its sales (over a million euros in total), relying on a very "lean" approach and by adapting its solution to the needs of its customers very early.

The strategy is now to scale up. *"Industrial demand for our solutions keeps growing. We want to be able to respond while maintaining our level of service and customer satisfaction.* explains Jonathan Macron, CEO of Redberry.

"We are delighted to support the Redberry team and participate in the deployment of its new technology in the service of public health. Its development will allow the creation of new jobs in our region in a sector, rapid microbiology, that is developing fast" says Christine Meyer -Forrier, CEO of SODIV.

Redberry strategic committee is strengthened with experts in Life Sciences.

After this first fundraising, the Redberry strategic committee welcomes new members whose experience, expertise and networks will be key assets for executing the company development strategy.

Dr. Henri Hagedé joins the Redberry strategic committee as an investor. A pharmacist and medical biologist, he brings a wealth of expertise in the medical field and clinical diagnosis.

Additional members will join the strategic committee by end of this year bringing in experiences in the development and deployment of innovative technologies in rapid microbiology and bioproduction.



About SODIV

With public and private shareholders, SODIV supports and finances regional SMEs in their job-creating projects. Acting for the regional economic vitality, SODIV intervenes by means of loans, bonds and equity. Since 1985, over a thousand projects have been financed, for nearly €94 million.

About Redberry SAS

Redberry is a private company specialized in devices and instrumentation for Life Sciences and Health, located in the East of France (Strasbourg area).

Redberry develops and commercializes fully automated systems for Rapid Microbiology applications.

Press contact : info@redberry.net